Is Lactoferrin more effective than inorganic iron in treating iron def anaemia in non-pregnant and if effective in pregnant women? 2 randomised trials

口服牛乳铁蛋白是一种新的，非传统的方法，以防止低出生体重，早产和新生儿死亡与孕产妇缺铁在低收入环境。全世界每年约有2000万低出生体重婴儿出生。低出生体重是由早产（婴儿出生早于预期）或胎儿生长迟缓引起的。在围产期保健服务有限的国家，出生体重不足和早产是新生儿死亡的主要原因。出生体重低的婴儿死亡的可能性是体重较重的婴儿的20倍或更多，其中大部分死亡负担是由于早产。目前针对孕妇使用铁补充剂（和叶酸）的范例往往失败，部分原因是副作用，这是在怀孕早期使用补充剂的强大障碍，这是缺铁妇女及其胎儿和未来新生儿的脆弱时期。此外，由于母体炎症和微量营养素缺乏阻碍了铁的有效利用，我们的方法将提供一种有效提供铁的产品，并且可以在关键干预窗口期间在怀孕早期服用，这有可能预防新生儿死亡。

Oral bovine lactoferrin is a novel, unconventional way to prevent low birthweight, preterm birth & neonatal deaths associated with maternal irondeficiency in low income settings. Each year about 20 million low birthweight babies are born worldwide. Low birthweight is caused by either preterm delivery (babies born earlier than expected) or fetal growth retardation. In countries where perinatal health services are limited, low birthweight and preterm birth are a major cause of neonatal deaths. Low birthweight babies are 20 or more times likely to die than heavier babies, with much of this mortality burden due to preterm birth. The current paradigm of using iron supplements (and folic acid) targeted at pregnant women often fails, in part because of the side effects, which are a strong barrier to use of the supplements early in pregnancy, a period of vulnerability for iron deficient women and their fetus and future newborn. And also because maternal inflammation and micronutrient deficiencies block effective utilization of iron Our approach will provide a product that will efficiently deliver iron and that can be taken early in pregnancy during a critical intervention window, which offers the potential to prevent neonatal deaths.